News | February 19, 2026
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Subscribe To Our Newsletter & Stay Updated
